{"success":true,"data":{"pressRelease":{"id":"51222","rtpr_id":"nPn5LfY90a","ticker":"VTGN","exchange":"NASDAQ","all_tickers":["VTGN"],"title":"Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm","author":"PR Newswire","published_at":"2026-06-01T18:40:00.020Z","article_body":"Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm\n\nPR Newswire\n\nNEW YORK, June 1, 2026\n\nNEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder\nlitigation law firm, is investigating whether certain officers and directors\nof Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties\nto shareholders.\n\n(https://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.html)\n\nAccording to a federal securities lawsuit, Insiders at Vistagen Therapeutics\ncaused the company to misrepresent or fail to disclose the risk of failure\ninherent in public speaking challenge-based Social Anxiety Disorder clinical\ntrials. Specifically, that from its own Phase 2 experience and published\nclinical research that public speaking challenge endpoints often exhibit\nelevated placebo responses, site variability and measurement noise, yet they\ncontinued to tout modifications made to the Phase 3 trial and presenting\nPALISADE-3 as likely to succeed.\n\nIf you currently own VTGN and purchased prior to April 01, 2024 please\ncontact Justin Kuehn, Esq. by email at justin@kuehn.law\n(mailto:justin@kuehn.law) or call (833) 672-0814. Kuehn Law pays all case\ncosts and does not charge its investor clients. Shareholders should contact\nthe firm immediately as there may be limited time to enforce your rights.\n\nWhy Your Participation Matters:\n\nAs a shareholder your voice matters, and by getting involved, you contribute\nto the integrity and fairness of the financial markets. Your investment. Your\nvoice. Your future.™\n\nFor additional information, please visit Shareholder Derivative Litigation -\nKuehn Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700932-1&h=910165961&u=https%3A%2F%2Fwww.kuehn.law%2Fservices%2Fshareholder-derivative-litigation&a=Shareholder+Derivative+Litigation+-+Kuehn+Law)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nContacts:\nKuehn Law, PLLC\nJustin Kuehn, Esq.\n53 Hill Street, Suite 605\nSouthampton, NY 11968\njustin@kuehn.law (mailto:justin@kuehn.law)\n(833) 672-0814\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html\n(https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html)\n\nSOURCE Kuehn Law, PLLC\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5LfY90a","title":"Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm","author":"PR Newswire","ticker":"VTGN","created":"2026-06-01T18:40:00.020Z","tickers":["VTGN"],"exchange":"NASDAQ","article_body":"Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm\n\nPR Newswire\n\nNEW YORK, June 1, 2026\n\nNEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder\nlitigation law firm, is investigating whether certain officers and directors\nof Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties\nto shareholders.\n\n(https://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.html)\n\nAccording to a federal securities lawsuit, Insiders at Vistagen Therapeutics\ncaused the company to misrepresent or fail to disclose the risk of failure\ninherent in public speaking challenge-based Social Anxiety Disorder clinical\ntrials. Specifically, that from its own Phase 2 experience and published\nclinical research that public speaking challenge endpoints often exhibit\nelevated placebo responses, site variability and measurement noise, yet they\ncontinued to tout modifications made to the Phase 3 trial and presenting\nPALISADE-3 as likely to succeed.\n\nIf you currently own VTGN and purchased prior to April 01, 2024 please\ncontact Justin Kuehn, Esq. by email at justin@kuehn.law\n(mailto:justin@kuehn.law) or call (833) 672-0814. Kuehn Law pays all case\ncosts and does not charge its investor clients. Shareholders should contact\nthe firm immediately as there may be limited time to enforce your rights.\n\nWhy Your Participation Matters:\n\nAs a shareholder your voice matters, and by getting involved, you contribute\nto the integrity and fairness of the financial markets. Your investment. Your\nvoice. Your future.™\n\nFor additional information, please visit Shareholder Derivative Litigation -\nKuehn Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700932-1&h=910165961&u=https%3A%2F%2Fwww.kuehn.law%2Fservices%2Fshareholder-derivative-litigation&a=Shareholder+Derivative+Litigation+-+Kuehn+Law)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nContacts:\nKuehn Law, PLLC\nJustin Kuehn, Esq.\n53 Hill Street, Suite 605\nSouthampton, NY 11968\njustin@kuehn.law (mailto:justin@kuehn.law)\n(833) 672-0814\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html\n(https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html)\n\nSOURCE Kuehn Law, PLLC\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-01T18:40:00.071111596Z","server_sent_at_ms":1780339200071},"received_at":"2026-06-01T18:40:00.126Z","source_url":"https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html"},"analysis":{"id":"40654","press_release_id":"51222","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kuehn Law issued a shareholder-solicitation notice naming Vistagen Therapeutics (VTGN); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Kuehn Law pays all case costs and does not charge its investor clients.","namedEntities":{"people":[{"name":"Justin Kuehn","role":"Attorney"}],"products":[],"companies":[{"name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","relationship":"target"},{"name":"Kuehn Law, PLLC","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Kuehn Law. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"VTGN"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kuehn Law issued a shareholder-solicitation notice naming Vistagen Therapeutics (VTGN); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Justin Kuehn","role":"Attorney"}],"products":[],"companies":[{"name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","relationship":"target"},{"name":"Kuehn Law, PLLC","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T18:40:32.362Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":32193,"modelName":"george-droid-qwen-72b"}}